Showing results (161-170 of 200) with videos related to
Sort By:
Pageof 20
Cancer Cell|November 22, 2024
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activationDavid Hsiehchen, Andrew Elliott, Joanne Xiu, et al.Gastroenterology|September 8, 2015
Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes From a Subset of Patients With Familial Colorectal CarcinomasSanjeevani Arora, Hong Yan, Iltaeg Cho, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2022
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerHedy L Kindler, Pascal Hammel, Michele Reni, et al.The New England Journal of Medicine|June 4, 2019
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic CancerTalia Golan, Pascal Hammel, Michele Reni, et al.The Journal of Molecular Diagnostics : JMD|August 25, 2019
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient SamplesSally E Trabucco, Kyle Gowen, Sophia L Maund, et al.Plos One|March 31, 2025
Aerobic exercise and brain structure among military service members and Veterans with varying histories of mild traumatic brain injury: A LIMBIC-CENC exploratory investigationSamuel R Walton, John J Fraser, Jessie R Oldham, et al.NPJ Precision Oncology|March 9, 2024
Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI)Eric C Anderson, John DiPalazzo, F Lee Lucas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2024
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO GuidelineNadine Tung, Charité Ricker, Hans Messersmith, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic AdenocarcinomaPhilip A Philip, Ibrahim Azar, Joanne Xiu, et al.Nature Cancer|March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancersMaishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.Pageof 20